University of Oxford retinal gene therapy company, Nightstar Therapeutics Ltd., files application to float on US NASDAQ.
Nightstar Therapeutics Ltd., a retinal gene therapy company spun out of the University of Oxford, UK, has filed a Form-1 with the United States SEC to raise up to $86.25M in an initial public offering on the NASDAQ Global Market. The company will adopt the symbol “NITE”. In their registration statement to float the company, […]Read full story
Systematic review of antioxidant vitamin and mineral use in preventing AMD suggests no benefit when analysed in >76,000 people
A systematic review and meta-analysis to determine whether or not taking antioxidant vitamin or mineral supplements, or both, prevent the development of AMD has found no evidence of benefit to their use. The study, conducted by researchers from the London School of Hygiene & Tropical Medicine and the City University of London, published their findings […]Read full story
Research published in Ophthalmologica shows aflibercept “treat and extend” (TAE) protocol is efficacious in typical AMD patients.
Research, reported in EURETINA’s professional journal, Ophthalmologica, has shown that a treat-and-extend (“TAE”) regimen using aflibercept for typical AMD appears effective for improving AMD and exudative changes. In addition the investigators commented that the exudation observed in participants may be suppressed with fewer treatments in classic choroidal neovascularisation (CNV), compared to occult CNV. The research, […]Read full story